General description
pCDF-1b质粒具有共表达能力以及表达具有N端His•Tag的融合蛋白的能力，该融合蛋白在纯化和切割后会产生天然蛋白。该质粒具有源自CloDF13（1）和链霉素/大观霉素抗性的来源，可以选择与许多其他基于Novagen T7的表达载体共表达。
该载体包含T7启动子、lac操纵子、核糖体结合位点(rbs)、氨基末端His•Tag
该产品包含转基因物种（GMO）。在欧盟范围内，转基因物种分别受欧洲议会和理事会的2001/18 /EC和2009/41/EC指令及其成员国中国家所实施规范的约束。该法规规定我们有义务索取您以及处理转基因生物的机构的相关信息。请点击这里获得最终用户声明（EUD）表格。
Other Notes
1.Nijkamp，H.J.J.，De Lang，R.，Stuitje，A.R.，Van Den Elzen P.J.M.，Veltkamp，E.，and Van Putten，A.J.(1986) Plasmid16，135–160.
2.Kim，J.S. and Raines，R.T.(1993) Protein Science2，348–356.
Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the “EMD Product”) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
毒性：标准处理（A）
| form | liquid |
| Quality Segment | 100 |
| manufacturer/tradename | Novagen® |
| storage condition | OK to freeze |
| storage temp. | −70°C |
